Searchable abstracts of presentations at key conferences in endocrinology

ea0029p89 | Adrenal cortex | ICEECE2012

Primary aldosteronism associated with subclinical Cushing syndrome

Tatsuoka H. , Honjo S. , Hamamoto Y. , Ohgita Y. , Mori K. , Fujimoto K. , Matsuoka A. , Ikeda H. , Wada Y. , Nishikawa T. , Sasano H. , Koshiyama H.

Introduction: It has been reported that primary aldosteronism(PA) is often associated with subclinical Cushing syndrome (SCS). In the present study, we investigated the frequency of SCS in subjects with PA.Method: Subjects included consecutive patients (n=43) who were diagnosed as PA between 2003 and 2011 in our institute. They were screened by plasma renin activity (PRA (ng/ml/h)) plasma aldosterone concentration (PAC (pg/mL)) ratio (ARR) above 2...

ea0029p1361 | Pituitary Clinical | ICEECE2012

Case series of diabetic ketoacidosis as the first presentation of 860 patients with acromegaly

Yoshida N. , Suzuki H. , Nagasawa K. , Okubo M. , Takeshita A. , Miyakawa M. , Mori Y. , Fukui T. , Fukuhara N. , Nishioka H. , Yamada S. , Takeuchi Y.

Background and aims: Excess GH causes insulin resistance resulting in impaired glucose metabolism. Although diabetes mellitus (DM) is common in patients with acromegaly, diabetic ketoacidosis (DKA) is rarely associated with acromegaly. Actually only 11 DKA patients have been anecdotally reported as the first presentation of acromegaly so far. Here we present nine cases of DKA as the first presentation of 860 consecutive patients with acromegaly and their clinical characteristi...

ea0029p1837 | Thyroid cancer | ICEECE2012

A novel tandem germline RET mutations on the same allele in a patient with MEN 2B

Nakao K. , Usui T. , Ikeda M. , Mori Y. , Kawashima S. , Nanba K. , Tamanaha T. , Tagami T. , Naruse M. , Yamamoto T. , Shimatsu A.

Multiple endocrine neoplasia type2 (MEN 2) (OMIM 171400) is an autosomal dominant inherited cancer syndrome caused by activating mutations in the RET proto-oncogene. MEN 2 is classified into three subtypes: MEN 2A, MEN 2B and familial medullary thyroid carcinoma(FMTC). MEN 2B accounts for 5–10% of MEN2 cases. More than 95% of MEN 2B patients carry M918T mutation of RET, and 2–3% harbor A883F mutation. There has been three reports of cases with MEN 2B phenotype caused...